TABLE 3.
Risk factors for 28-day mortality in hospitalized lung and non-lung solid-organ transplant recipients with COVID-19, univariable logistic regression models
| Covariate | Lung (n = 120) |
Non-lung (n = 961) |
All SOTR (n = 1081) |
|||
|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | p-value | Unadjusted OR ratio (95% CI) | p-value | Unadjusted OR ratio (95% CI) | p-value | |
| Age >65 years | 1.3 (0.6–3.0) | .6 | 2.3 (1.6–3.3) | <.001 | 2.1 (1.6–3.0) | <.001 |
| Male sex | 0.6 (0.3–1.3) | .2 | 1.2 (0.8–1.7) | .44 | ||
| Black racea | 0.5 (0.2–1.6) | .3 | 1.1 (0.7–1.5) | .74 | 1.0 (0.7–1.4) | .84 |
| Latinx or Hispanic ethnicity | 1.0 (0.3–2.7) | >.9 | 0.9 (0.6–1.4) | .7 | 0.9 (0.6–1.3) | .6 |
| Region (vs. Midwest) | ||||||
| Northeast | 1.7 (0.3–9.5) | .6 | 0.9 (0.5–1.6) | .7 | 0.9 (0.5–1.6) | .79 |
| South | 1.6 (0.3–8.9) | .5 | 0.8 (0.5–1.4) | .4 | 0.8 (0.5–1.5) | .54 |
| West | 1.8 (0.3–9.4) | .5 | 0.8 (0.4–1.6) | .6 | 1.0 (0.5–1.8) | .91 |
| Organa | ||||||
| Lung | 2.6 (1.0–2.6) | .04 | ||||
| Single lung transplant | 2.2 (0.9–5.3) | .08 | ||||
| Heart | – | 0.7 (0.5–1.3) | .3 | 0.7 (0.4–1.2) | .15 | |
| Liver | – | 0.9 (0.5–1.4) | .6 | 0.8 (0.5–1.3) | .40 | |
| Kidney | – | 1.1 (0.8–1.7) | .5 | 0.9 (0.7–1.3) | ||
| Comorbidities | ||||||
| Hypertension | 0.6 (0.3–1.5) | .3 | 2.2 (1.3–3.7) | .004 | 1.4 (0.9–2.1) | .12 |
| Diabetes mellitus | 0.8 (0.3–1.8) | .5 | 1.9 (1.3–2.7) | .001 | 1.6 (1.2–2.2) | .003 |
| Heart failure | 1.05 (0.2–5.5) | >.9 | 3.8 (2.2–6.6) | <.001 | 3.2 (1.9–5.5) | <.001 |
| Obesity (BMI ≥30 kg/m2) | 2.0 (0.8–5.2) | .2 | 1.6 (1.1–2.2) | .02 | 1.5 (1.1–2.1) | .008 |
| Chronic kidney disease | 1.2 (0.5–2.8) | .7 | 1.3 (0.9–1.8) | .2 | 1.29 (0.9–1.8) | .11 |
| Coronary artery disease | 0.6 (0.2–2.0) | .4 | 1.6 (1.1–2.4) | .03 | 1.4 (1.0–2.1) | .07 |
| Chronic lung disease | 2.9 (1.0–8.7) | .06 | 4.1 (2.4–7.3) | <.001 | 4.0 (2.4–6.6) | <.001 |
| CLAD | 2.9 (1.0–8.7) | .06 | ||||
| Immunosuppression | ||||||
| Recent induction therapy | – | >.99 | 0.5 (0.2–1.3) | .2 | 0.5 (0.2–1.2) | .1 |
| CNI, anti-metabolite, and steroids use | 1.9 (0.7–5.1) | .2 | 0.9 (0.6–1.2) | .5 | 1.0 (0.7–1.4) | >.9 |
| Any CNI containing regimen | – | >.99 | 1.2 (0.7–2.2) | .5 | 1.3 (0.7–2.5) | .4 |
| Any anti-metabolite containing regimen | 1.7 (0.6–4.6) | .3 | 0.9 (0.6–1.3) | .5 | 0.9 (0.7–1.3) | .8 |
| Any steroid containing regimen | 0.6 (0.1–7.2) | .7 | 1.1 (0.7–1.6) | .7 | 1.1 (0.8–1.6) | .5 |
| Any mTOR containing regimen | 0.4 (0.0–3.1) | .4 | 0.2 (0.1–0.8) | .03 | 0.3 (0.1–0.8) | .02 |
Abbreviations: BMI, body mass index; CI, confidence interval; CLAD, chronic lung allograft dysfunction; CNI, calcineurin inhibitor; mTOR, mammalian target of rapamycin; OR, odds ratio.
a
Refers to patients who received a transplant of the specified organ, with or without transplant other organs: lung (n = 120), heart (n = 133), liver (n = 155), kidney (n = 723). Reference is no transplant of the listed organ.